|
Takeda
Reportedly Buying Out Abbott’s Stake in US Joint Venture;
Abbott Hit by Antitrust Suit
Takeda
Pharmaceutical Co. is allegedly planning to spend about $5 billion
to buy out Abbott Laboratories in their 50-50 US venture, TAP
Pharmaceutical Products. The deal would be the biggest overseas
acquisition by a Japanese drug firm. Reuters
(3/19)
Regulators from 18 states and the District of Columbia are suing
Abbott Laboratories and Solvay unit Fournier, alleging the
drugmakers illegally conspired to prevent and delay low-cost
generic versions of their TriCor (fenofibrate) cholesterol drug. Reuters
(3/18)
|
